Regeneron Pharmaceuticals

mibavademab

clinicaltrials.gov

ALN-CIDEB

clinicaltrials.gov

Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Phase 3Not yet recruiting20261,500 people2 Oct 2026clinicaltrials.gov

NCT07715734

CollaboratorPhase 2Not yet recruiting202622 people20 Jul 2026clinicaltrials.gov

NCT07624513

CollaboratorPhase 3Not yet recruiting2026720 people3 Jun 2026clinicaltrials.gov

NCT07527910

Phase 2Recruiting2026204 people14 Apr 2026clinicaltrials.gov

NCT07477704

Phase 2Recruiting2026420 people17 Mar 2026clinicaltrials.gov

NCT07428369

Phase 2/3Withdrawn20260 people23 Feb 2026clinicaltrials.gov

NCT07271186

Phase 2Recruiting2026195 people9 Dec 2025clinicaltrials.gov

A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

Phase 2Recruiting202634 people19 Nov 2025clinicaltrials.gov

NCT07234058

CollaboratorPhase 2Recruiting2026126 people18 Nov 2025clinicaltrials.gov

NCT07222761

Phase 3Recruiting2026915 people30 Oct 2025clinicaltrials.gov

NCT07213778

Phase 3Recruiting20252,000 people9 Oct 2025clinicaltrials.gov

NCT06932562

CollaboratorPhase 3Recruiting20251,000 people17 Apr 2025clinicaltrials.gov

NCT06616584

CollaboratorPhase 2/3Recruiting2025378 people27 Sept 2024clinicaltrials.gov

NCT06571708

CollaboratorPhase 2Recruiting202536 people26 Aug 2024clinicaltrials.gov

NCT06444178

Phase 1Completed2024224 people5 Jun 2024clinicaltrials.gov

NCT06385262

CollaboratorPhase 2Suspended202563 people26 Apr 2024clinicaltrials.gov

NCT06373146

CollaboratorPhase 2Completed2024392 people18 Apr 2024clinicaltrials.gov

NCT06299098

Phase 2Active, not recruiting20241,005 people7 Mar 2024clinicaltrials.gov

NCT06230224

Phase 3Active, not recruiting2024216 people30 Jan 2024clinicaltrials.gov

NCT06097364

Phase 3Active, not recruiting2023733 people24 Oct 2023clinicaltrials.gov